BMO Capital raised the firm’s price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The ...

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed ...

General and administrative expenses were $10.6 million for the quarter ended September 30, 2024, compared to $6.0 million for the same period in 2023. The increase was primarily attributable to ...

Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from healthcare providers and payers in the U.S.UK ...